Legend Biotech (9LB) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

9LB Analyst Ratings

Moderate Buy

7 Buy

3 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Legend

Biotech

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

9LB Stock 12 Month Forecast

Average Price Target

€45.47

▲(131.99% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Legend Biotech in the last 3 months. The average price target is €45.47 with a high forecast of €69.49 and a low forecast of €24.32. The average price target represents a 131.99% change from the last price of €19.60.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"€13","70":"€70","27.25":"€27.3","41.5":"€41.5","55.75":"€55.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":69.4871504,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€69.49</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45.470654043,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€45.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.32050264,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€24.32</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,27.25,41.5,55.75,70],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16,20.114396184615387,24.22879236923077,28.343188553846154,32.45758473846154,36.57198092307693,40.68637710769231,44.800773292307696,48.91516947692308,53.02956566153847,57.14396184615386,61.25835803076924,65.37275421538462,{"y":69.4871504,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16,18.266973387923077,20.533946775846154,22.800920163769234,25.067893551692308,27.334866939615388,29.601840327538465,31.868813715461542,34.135787103384615,36.402760491307696,38.669733879230776,40.93670726715385,43.20368065507693,{"y":45.470654043,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16,16.640038664615385,17.28007732923077,17.920115993846153,18.56015465846154,19.200193323076924,19.84023198769231,20.480270652307695,21.120309316923077,21.760347981538462,22.400386646153848,23.04042531076923,23.68046397538462,{"y":24.32050264,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":33.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.3,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.4,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€69.49

Average Price Target€45.47

Lowest Price Target€24.32

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Mitchell Kapoor

H.C. Wainwright

€56.46

Buy

188.05%

Upside

Reiterated

07/28/26

Buy Rating Reiterated as Strong CARVYKTI Momentum and Attractive Valuation Support Unchanged $65 Price Target

Leonid Timashev

RBC Capital

€54.72→€51.25

Buy

161.46%

Upside

Reiterated

07/27/26

Analysts Offer Insights on Healthcare Companies: Tenet Healthcare (NYSE: THC), Legend Biotech (NASDAQ: LEGN) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Ashwani Verma

UBS

€42.56→€24.32

Hold

24.08%

Upside

Downgraded

07/24/26

Legend Biotech downgraded to Neutral from Buy at UBSLegend Biotech downgraded to Neutral from Buy at UBS

Ziyi Chen

Goldman Sachs

€35.98→€35.18

Buy

79.48%

Upside

Reiterated

07/15/26

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN) and Urogen Pharma (NASDAQ: URGN)

Etzer Darout

Barclays

€69.49

Buy

254.53%

Upside

Reiterated

07/14/26

Barclays Sticks to Its Buy Rating for Legend Biotech (LEGN)

Jessica Fye

J.P. Morgan

€30.4

Hold

55.11%

Upside

Initiated

07/13/26

Legend Biotech resumed with a Neutral at JPMorganLegend Biotech resumed with a Neutral at JPMorgan

Edward Tenthoff

Piper Sandler

€55.59

Buy

183.62%

Upside

Reiterated

06/15/26

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Ascendis Pharma (NASDAQ: ASND) and Lyell Immunopharma (NASDAQ: LYEL)

Kostas Biliouris

Oppenheimer

€65.14

Buy

232.37%

Upside

Reiterated

06/15/26

Legend Biotech (LEGN) Receives a Buy from Oppenheimer

Yaron Werber

TD Cowen

€18.24→€25.19

Hold

28.52%

Upside

Assigned

05/13/26

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Tvardi Therapeutics (NASDAQ: TVRD) and Organigram Global (NASDAQ: OGI)

Terence Flynn

Morgan Stanley

€42.56→€41.69

Buy

112.72%

Upside

Reiterated

05/13/26

Legend Biotech price target lowered to $48 from $49 at Morgan StanleyLegend Biotech price target lowered to $48 from $49 at Morgan Stanley

Asthika Goonewardene

Truist Financial

€60.8

Buy

210.21%

Upside

Reiterated

03/13/26

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN) and Medtronic (NYSE: MDT)

James Shin

Deutsche Bank

€52.12

Buy

165.89%

Upside

Reiterated

03/09/26

Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Lantheus (LNTH)

Qize Ding

Rothschild & Co Redburn

€72.09→€20.85

Hold

6.36%

Upside

Downgraded

02/12/26

Legend Biotech downgraded to Neutral from Buy at Rothschild & Co RedburnLegend Biotech downgraded to Neutral from Buy at Rothschild & Co Redburn

Eric Schmidt FCA

Cantor Fitzgerald

€65.14→€64.28

Buy

227.94%

Upside

Reiterated

12/17/25

Legend Biotech price target lowered to $74 from $75 at Cantor FitzgeraldLegend Biotech price target lowered to $74 from $75 at Cantor Fitzgerald

Sami Corwin

William Blair

―

Hold

―

Reiterated

11/12/25

Legend Biotech's Strategic Growth and Risks: Analyst Assigns Hold Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Mitchell Kapoor

H.C. Wainwright

€56.46

Buy

188.05%

Upside

Reiterated

07/28/26

Buy Rating Reiterated as Strong CARVYKTI Momentum and Attractive Valuation Support Unchanged $65 Price Target

Leonid Timashev

RBC Capital

€54.72→€51.25

Buy

161.46%

Upside

Reiterated

07/27/26

Analysts Offer Insights on Healthcare Companies: Tenet Healthcare (NYSE: THC), Legend Biotech (NASDAQ: LEGN) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Ashwani Verma

UBS

€42.56→€24.32

Hold

24.08%

Upside

Downgraded

07/24/26

Legend Biotech downgraded to Neutral from Buy at UBSLegend Biotech downgraded to Neutral from Buy at UBS

Ziyi Chen

Goldman Sachs

€35.98→€35.18

Buy

79.48%

Upside

Reiterated

07/15/26

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN) and Urogen Pharma (NASDAQ: URGN)

Etzer Darout

Barclays

€69.49

Buy

254.53%

Upside

Reiterated

07/14/26

Barclays Sticks to Its Buy Rating for Legend Biotech (LEGN)

Jessica Fye

J.P. Morgan

€30.4

Hold

55.11%

Upside

Initiated

07/13/26

Legend Biotech resumed with a Neutral at JPMorganLegend Biotech resumed with a Neutral at JPMorgan

Edward Tenthoff

Piper Sandler

€55.59

Buy

183.62%

Upside

Reiterated

06/15/26

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Ascendis Pharma (NASDAQ: ASND) and Lyell Immunopharma (NASDAQ: LYEL)

Kostas Biliouris

Oppenheimer

€65.14

Buy

232.37%

Upside

Reiterated

06/15/26

Legend Biotech (LEGN) Receives a Buy from Oppenheimer

Yaron Werber

TD Cowen

€18.24→€25.19

Hold

28.52%

Upside

Assigned

05/13/26

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Tvardi Therapeutics (NASDAQ: TVRD) and Organigram Global (NASDAQ: OGI)

Terence Flynn

Morgan Stanley

€42.56→€41.69

Buy

112.72%

Upside

Reiterated

05/13/26

Legend Biotech price target lowered to $48 from $49 at Morgan StanleyLegend Biotech price target lowered to $48 from $49 at Morgan Stanley

Asthika Goonewardene

Truist Financial

€60.8

Buy

210.21%

Upside

Reiterated

03/13/26

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN) and Medtronic (NYSE: MDT)

James Shin

Deutsche Bank

€52.12

Buy

165.89%

Upside

Reiterated

03/09/26

Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Lantheus (LNTH)

Qize Ding

Rothschild & Co Redburn

€72.09→€20.85

Hold

6.36%

Upside

Downgraded

02/12/26

Legend Biotech downgraded to Neutral from Buy at Rothschild & Co RedburnLegend Biotech downgraded to Neutral from Buy at Rothschild & Co Redburn

Eric Schmidt FCA

Cantor Fitzgerald

€65.14→€64.28

Buy

227.94%

Upside

Reiterated

12/17/25

Legend Biotech price target lowered to $74 from $75 at Cantor FitzgeraldLegend Biotech price target lowered to $74 from $75 at Cantor Fitzgerald

Sami Corwin

William Blair

―

Hold

―

Reiterated

11/12/25

Legend Biotech's Strategic Growth and Risks: Analyst Assigns Hold Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Legend Biotech

3 Months

Justin ZelinBTIG

Success Rate

12/32 ratings generated profit

Average Return

-1.53%

Copying Justin Zelin's trades and holding each position for 3 Months would result in 37.50% of your transactions generating a profit, with an average return of -1.53% per trade.

1 Year

Justin ZelinBTIG

Success Rate

12/32 ratings generated profit

Average Return

-9.47%

Copying Justin Zelin's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -9.47% per trade.

2 Years

Justin ZelinBTIG

Success Rate

12/32 ratings generated profit

Average Return

-12.09%

Copying Justin Zelin's trades and holding each position for 2 Years would result in 37.50% of your transactions generating a profit, with an average return of -12.09% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

9LB Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 9LB has received 15 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 9LB average Analyst price target in the past 3 months is 45.47.

Each month's total comprises the sum of three months' worth of ratings.

9LB Financial Forecast

9LB Earnings Forecast

Next quarter’s earnings estimate for 9LB is €0.05 with a range of -€0.09 to €0.20. The previous quarter’s EPS was -€0.13. 9LB beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.49% of the time in the same period. In the last calendar year 9LB has Performed in-line its overall industry.

9LB Sales Forecast

Next quarter’s sales forecast for 9LB is €312.98M with a range of €293.65M to €339.39M. The previous quarter’s sales results were €269.06M. 9LB beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 50.39% of the time in the same period. In the last calendar year 9LB has Outperformed its overall industry.

9LB Stock Forecast FAQ

What is DE:9LB’s average 12-month price target, according to analysts?

Based on analyst ratings, Legend Biotech Corporation’s 12-month average price target is 45.47.

What is DE:9LB’s upside potential, based on the analysts’ average price target?

Legend Biotech Corporation has 131.99% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Legend Biotech Corporation a Buy, Sell or Hold?

Legend Biotech Corporation has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 3 hold ratings and 0 sell ratings.

What is Legend Biotech Corporation’s share price target?

The average share price target for Legend Biotech Corporation is 45.47. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €69.49 ,and the lowest forecast is €24.32. The average share price target represents 131.99% Increase from the current price of €19.6.

What do analysts say about Legend Biotech Corporation?

Legend Biotech Corporation’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of Legend Biotech Corporation?

To buy shares of DE:9LB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Legend Biotech (9LB) Stock Forecast & Price Target

9LB Analyst Ratings

9LB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Legend Biotech

9LB Analyst Recommendation Trends

9LB Financial Forecast

9LB Earnings Forecast

9LB Sales Forecast

9LB Stock Forecast FAQ

Detailed List of Analyst Forecasts